China Medical News

Japanese pharmaceutical company Takeda and domestic biotech company Belief BioMed jointly announced on Thursday that the gene therapy drug Dalnacogene Ponparvovec Injection has received approval from China's National Medical Products Administration for the treatment of moderate to severe hemophilia B in adult patients, marking the first approved gene therapy drug for the disease in the country.

This innovative injection was developed and produced by Belief BioMed, while Takeda China is responsible for its commercialization on the Chinese mainland as well as Hong Kong and Macao. The two parties will leverage their respective strengths to accelerate the provision of this gene therapy to patients and jointly explore new frontiers in hemophilia B treatment.

Professor Zhang Lei from the Blood Disease Hospital of the Chinese Academy of Medical Sciences, who was also the leading investigator of the drug's registration clinical trials, said the approval of the therapy brings revolutionary hope to Chinese patients suffering from the disease. "By receiving a single dosing, patients will have a reduced risk of bleeding and joint damage, and they can potentially overcome the burden of lifelong frequent intravenous injections," said Zhang.

"We believe that with continuous breakthroughs in scientific research and the accumulation of clinical experience, the treatment of hemophilia will enter a new era, offering patients a higher quality of life," he said. (Source: China Daily)